Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
20
07
2021
accepted:
26
05
2022
revised:
23
05
2022
pubmed:
15
6
2022
medline:
31
8
2022
entrez:
14
6
2022
Statut:
ppublish
Résumé
Noninvasive disease monitoring and risk stratification by circulating tumor DNA (ctDNA) profiling has become a potential novel strategy for patient management in B-cell lymphoma. Emerging innovative therapeutic options and an unprecedented growth in our understanding of biological and molecular factors underlying lymphoma heterogeneity have fundamentally increased the need for precision-based tools facilitating personalized and accurate disease profiling and quantification. By capturing the entire mutational landscape of tumors, ctDNA assessment has some decisive advantages over conventional tissue biopsies, which usually target only one single tumor site. Due to its non- or minimal-invasive nature, serial and repeated ctDNA profiling provides a real-time picture of the genetic composition and facilitates quantification of tumor burden any time during the course of the disease. In this review, we present a comprehensive overview of technologies used for ctDNA detection and genotyping in B-cell lymphoma, focusing on pre-analytical and technical requirements, the advantages and limitations of various approaches, and highlight recent advances around improving sensitivity and suppressing technical errors. We broadly review potential applications of ctDNA in clinical practice and for translational research by describing how ctDNA might enhance lymphoma subtype classification, treatment response assessment, outcome prediction, and monitoring of measurable residual disease. We finally discuss how ctDNA could be implemented in prospective clinical trials as a novel surrogate endpoint and be utilized as a decision-making tool to guide lymphoma treatment in the future.
Identifiants
pubmed: 35701522
doi: 10.1038/s41375-022-01618-w
pii: 10.1038/s41375-022-01618-w
pmc: PMC9417989
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating Tumor DNA
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2151-2164Informations de copyright
© 2022. The Author(s).
Références
Haematologica. 2020 Feb 20;106(1):154-162
pubmed: 32079702
Blood. 2019 Jan 31;133(5):436-445
pubmed: 30567753
J Clin Oncol. 2021 Sep 20;39(27):3034-3043
pubmed: 34133196
Nat Biotechnol. 2022 Apr;40(4):585-597
pubmed: 35361996
Blood. 2022 Mar 24;139(12):1780-1781
pubmed: 35323879
Lancet Oncol. 2017 Aug;18(8):1076-1088
pubmed: 28668386
Nat Med. 2018 May;24(5):679-690
pubmed: 29713087
Blood. 2017 Jul 27;130(4):440-452
pubmed: 28600337
Recent Results Cancer Res. 2020;215:213-230
pubmed: 31605231
Haematologica. 2018 Jun;103(6):e241-e244
pubmed: 29472348
N Engl J Med. 2014 Dec 25;371(26):2477-87
pubmed: 25426838
Blood Adv. 2018 Apr 10;2(7):807-816
pubmed: 29636326
Surg Neurol. 2006;65 Suppl 1:S1:27-1:32
pubmed: 16427444
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
Leukemia. 2020 Feb;34(2):522-532
pubmed: 31462735
N Engl J Med. 2002 Jun 20;346(25):1937-47
pubmed: 12075054
Cancer Treat Rev. 2020 Dec;91:102106
pubmed: 33049623
Br J Haematol. 2019 Jun;185(5):974-977
pubmed: 30408153
Blood Adv. 2021 Dec 28;5(24):5525-5535
pubmed: 34551072
N Engl J Med. 2018 Mar 29;378(13):1211-1223
pubmed: 29590547
Blood. 2022 Mar 24;139(12):1863-1877
pubmed: 34932792
Blood. 2015 Jun 11;125(24):3679-87
pubmed: 25887775
Lancet Haematol. 2021 Jan;8(1):e67-e79
pubmed: 33357485
Br J Haematol. 2021 Jun;193(5):867-881
pubmed: 33550600
Blood. 2008 Jan 15;111(2):558-65
pubmed: 17962512
Oncotarget. 2016 Jun 21;7(25):38180-38190
pubmed: 27224912
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Med. 2021 Oct 8;2(10):1171-1193.e11
pubmed: 35590205
J Clin Oncol. 2017 Nov 1;35(31):3538-3546
pubmed: 28862883
Leuk Lymphoma. 2019 Dec;60(14):3587-3589
pubmed: 31305194
Int J Clin Exp Pathol. 2015 Jul 01;8(7):7798-808
pubmed: 26339344
J Clin Oncol. 2011 May 10;29(14):1827-34
pubmed: 21483014
EJHaem. 2021 May 12;2(3):616-627
pubmed: 35844685
Nature. 2001 Jul 19;412(6844):341-6
pubmed: 11460166
Oncotarget. 2017 Jan 31;8(5):8765-8774
pubmed: 28060738
Clin Cancer Res. 2021 Jan 15;27(2):513-521
pubmed: 33122345
Genome Med. 2020 Feb 28;12(1):23
pubmed: 32111235
Haematologica. 2021 Feb 01;106(2):513-521
pubmed: 32079701
J Clin Oncol. 2010 Apr 10;28(11):1896-903
pubmed: 20212248
Blood. 2014 Feb 20;123(8):1214-7
pubmed: 24398326
J Neurosci Rural Pract. 2014 Jan;5(1):32-9
pubmed: 24741247
J Clin Oncol. 2018 Jul 10;36(20):2024-2034
pubmed: 29750632
Blood. 2004 Sep 1;104(5):1258-65
pubmed: 15126323
J Clin Oncol. 2014 Nov 1;32(31):3506-12
pubmed: 25267745
Cancer Sci. 2018 Jan;109(1):225-230
pubmed: 29151258
Leuk Lymphoma. 2016;57(1):151-60
pubmed: 25860234
Blood. 2011 Jun 30;117(26):7070-8
pubmed: 21536860
Genes (Basel). 2020 Jul 13;11(7):
pubmed: 32668764
J Clin Invest. 2012 Oct;122(10):3424-31
pubmed: 23023713
PLoS Med. 2016 Dec 13;13(12):e1002197
pubmed: 27959929
Sci Transl Med. 2016 Nov 9;8(364):364ra155
pubmed: 27831904
Mol Biol Rep. 2020 Oct;47(10):8179-8187
pubmed: 33029702
Oncotarget. 2016 Aug 9;7(32):51494-51502
pubmed: 27285986
Cancer Cell. 2023 Jan 9;41(1):210-225.e5
pubmed: 36584673
N Engl J Med. 2008 Nov 27;359(22):2313-23
pubmed: 19038878
Oncotarget. 2017 Jul 18;8(29):48157-48168
pubmed: 28636991
Cancer Discov. 2019 Apr;9(4):500-509
pubmed: 30578357
Haematologica. 2017 Feb;102(2):356-363
pubmed: 28143954
Nat Med. 2015 Aug;21(8):922-6
pubmed: 26193343
Hematol Oncol. 2018 Apr;36(2):429-435
pubmed: 29210102
Brain Tumor Pathol. 2006 Oct;23(2):71-5
pubmed: 18095122
JCO Oncol Pract. 2020 Sep;16(9):561-568
pubmed: 32421389
BMC Cancer. 2019 Mar 1;19(1):192
pubmed: 30823914
Blood. 2021 Mar 18;137(11):1491-1502
pubmed: 33512416
Nat Med. 2014 May;20(5):548-54
pubmed: 24705333
Blood. 2021 Aug 5;138(5):382-386
pubmed: 33735913
J Clin Oncol. 2021 Apr 20;39(12):1317-1328
pubmed: 33621109
Blood Adv. 2022 Apr 26;6(8):2667-2680
pubmed: 35143622
Cancers (Basel). 2021 May 28;13(11):
pubmed: 34071407
J Clin Oncol. 2015 May 1;33(13):1467-74
pubmed: 25823735
Blood. 2018 May 31;131(22):2413-2425
pubmed: 29449275
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14508-13
pubmed: 22853953
N Engl J Med. 2013 Oct 31;369(18):1681-90
pubmed: 24171516
Blood Cancer J. 2021 Apr 5;11(4):68
pubmed: 33820908
Br J Haematol. 2021 May;193(3):497-505
pubmed: 33620087
Blood. 2017 Sep 14;130(11):1315-1326
pubmed: 28701367
N Engl J Med. 2022 Feb 17;386(7):640-654
pubmed: 34891224
Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1116-25
pubmed: 25713363
Blood. 2017 Apr 6;129(14):1947-1957
pubmed: 28096087
Arch Pathol Lab Med. 2013 Nov;137(11):1610-8
pubmed: 24168498
Diagnostics (Basel). 2020 Aug 02;10(8):
pubmed: 32748806
Cell. 2019 Jul 25;178(3):699-713.e19
pubmed: 31280963
Nat Biotechnol. 2021 Dec;39(12):1537-1547
pubmed: 34294911
Br J Haematol. 2015 Jul;170(1):56-65
pubmed: 25823885
Nat Rev Genet. 2022 Jun;23(6):323
pubmed: 35422499
Blood Cancer J. 2018 Aug 1;8(8):74
pubmed: 30069017
J Clin Oncol. 2021 Aug 10;39(23):2605-2616
pubmed: 33909455
Cell Rep. 2014 Jan 16;6(1):130-40
pubmed: 24388756
Lancet Oncol. 2015 May;16(5):541-9
pubmed: 25842160
Nat Med. 2020 Jul;26(7):1041-1043
pubmed: 32572266
Sci Transl Med. 2015 Jun 24;7(293):293ra104
pubmed: 26109104
Br J Haematol. 2018 May;181(3):306-319
pubmed: 29359797
Nat Med. 2019 Jan;25(1):119-129
pubmed: 30455436
Nat Rev Cancer. 2017 Apr;17(4):223-238
pubmed: 28233803
Hematol Oncol. 2019 Jun;37 Suppl 1:70-74
pubmed: 31187522
World Neurosurg. 2015 Oct;84(4):1084-9
pubmed: 26008141
Nat Protoc. 2014 Nov;9(11):2586-606
pubmed: 25299156
J Clin Oncol. 2007 Jul 20;25(21):3168-73
pubmed: 17577023
Blood. 2003 Sep 15;102(6):1989-96
pubmed: 12676776
Blood Adv. 2020 Jul 14;4(13):2886-2898
pubmed: 32589730
Nature. 2020 Apr;580(7802):245-251
pubmed: 32269342
Pract Lab Med. 2019 Jun 18;16:e00125
pubmed: 31289732
Hematology Am Soc Hematol Educ Program. 2012;2012:397-401
pubmed: 23233610
Nat Biotechnol. 2016 May;34(5):547-555
pubmed: 27018799
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Hematol Oncol. 2020 Feb;38(1):34-37
pubmed: 31872890
Leukemia. 2020 Jan;34(1):151-166
pubmed: 31431735
Blood. 2004 Jan 1;103(1):275-82
pubmed: 14504078
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2017-22
pubmed: 24902639
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877
Curr Treat Options Gastroenterol. 2020 Jan 21;:
pubmed: 31965446
J Clin Oncol. 2019 May 20;37(15):1285-1295
pubmed: 30901302
Lancet Oncol. 2020 Nov;21(11):1433-1442
pubmed: 33035457
Haematologica. 2016 Sep;101(9):1094-101
pubmed: 27479820
Blood. 2016 Jul 14;128(2):185-94
pubmed: 27166360
Nat Med. 2019 Dec;25(12):1928-1937
pubmed: 31768066
J Clin Oncol. 2018 Oct 1;36(28):2845-2853
pubmed: 30125215